Melatonin and human cardiovascular disease

• Autores: Pandi Perumal, Seithikurippu R.; BaHammam, Ahmed S.; Ojike, Nwakile I.; Akinseye, Oluwaseun; Kendzerska, Tetyana; Buttoo, Kenneth; Dhandapany, Perundurai S.; Brown, Gregory M.; Cardinali, Daniel Pedro
• Año de publicación: 2017
• Idioma: inglés
• Tipo de recurso: artículo
• Fuente: Preprint del documento publicado en Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 22, N° 2, 2017
• Materia: MEDICINA; MELATONINA; PRESION SANGUINEA; ENFERMEDADES CARDIOVASCULARES; HIPERTENSION
• Institución: Pontificia Universidad Católica Argentina

Fil: Pandi Perumal, Seithikurippu R. King Saud University. College of Medicine. Departament of Medicina. The University Sleep Disorders Center; Saudi Arabia
Fil: BaHammam, Ahmed S. King Saud University. College of Medicine. Departament of Medicina. The University Sleep Disorders Center; Saudi Arabia
Fil: Ojike, Nwakile I. New York University Medical Center. Department of Population Health. Division of Health and Behavior. Center for Healthful Behavior Change; Estados Unidos
Fil: Akinseye, Oluwaseun. Queens Hospital Center. Icahn School of Medicine at Mount Sinai. Department of Internal Medicine; Estados Unidos
Fil: Akinseye, Oluwaseun. Brooklyn College. City University of New York School of Public Health. Estados Unidos
Fil: Kendzerska, Tetyana. Sunnybrook Health Sciences Center. Institute for Clinical Evaluative Science; Canada
Fil: Buttoo, Kenneth. Sleep Disorders Center; Canada
Fil: Dhandapany, Perundurai S. Oregon Health and Science University. Departments of Medicine, Molecular and Medical Genetics. Knight Cardiovascular Institute; Estados Unidos
Fil: Dhandapany, Perundurai S. Institute for Stem Cell Biology and Regenerative Medicine. Centre for Cardiovascular Biology and Disease; India
Fil: Brown, Gregory M. University of Toronto. Centre for Addiction and Mental Health; Canada
Fil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
Fil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Abstract: The possible therapeutic role of melatonin in the pathophysiology of coronary artery disorder (CAD) is increasingly being recognized. In humans, exogenous melatonin has been shown to decrease nocturnal hypertension, improve systolic and diastolic blood pressure, reduce the pulsatility index in the internal carotid artery, decrease platelet aggregation and reduce serum catecholamine levels. Low circulating levels of melatonin are reported in individuals with CAD, arterial hypertension and congestive heart failure. This review assesses current literature on the cardiovascular effects of melatonin in humans. It can be concluded that melatonin deserves to be considered in clinical trials evaluating novel therapeutic interventions for cardiovascular disorders.